4,504 results
Search Results
152. Editorial: time to modify practice and use the modified Rutgeert's score.
153. Editorial: a paradigm shift in NUDT15 assessment—towards predictive and personalised medicine in Crohn's disease? Authors' reply.
154. Editorial: infections and hepatic encephalopathy–does the chicken or the egg come FIRST? A novel perspective at the horizon.
155. Editorial: suboptimal ultrasound visualisation in patients undergoing surveillance for hepatocellular carcinoma.
156. Editorial: anti‐TNF combination therapy for inflammatory bowel disease–one size does not fit all.
157. Letter: the potential link between oesophageal hypervigilance, visceral anxiety, increased swallow rate and oesophageal mucosal integrity—authors' reply.
158. Editorial: a paradigm shift in NUDT15 assessment—towards predictive and personalised medicine in Crohn's disease?
159. Editorial: protecting hypoxia‐inducible factor 1a and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis? Authors' reply.
160. Letter: the potential link between oesophageal hypervigilance, visceral anxiety, increased swallow rate and oesophageal mucosal integrity.
161. Editorial: protecting hypoxia‐inducible factor‐1α and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis?
162. Letter: systematic review with meta‐analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B—authors' reply.
163. Letter: association of laboratory indexes and magnetic resonance elastography‐associated liver stiffness with complications and mortality.
164. Letter: you can stare at a vicious circle, but you can also try to break it—psychological health and coeliac disease. Authors' reply.
165. Letter: severe COVID‐19 infection and biologic therapies—a cohort study of 7 808 patients in France.
166. Letter: recognising frailty in patients with inflammatory bowel disease is crucial for appropriate personalised treatment.
167. Editorial: first‐degree relatives of Mexican Americans with HCC are at increased risk of significant fibrosis—authors' reply.
168. Letter: grouping traditional biomarkers that are within reach has great utility – further validation is needed.
169. Letter: disentangling the role of redox‐active compounds in the development of inflammatory bowel diseases – moving towards causal associations.
170. Letter: disentangling the role of redox‐active compounds in the development of inflammatory bowel diseases—moving towards causal associations. Authors' reply.
171. Editorial: clinical outcomes in lean NAFLD – the devil is in the details. Authors' reply.
172. Editorial: Why are patients with Crohn's disease still treated with 5‐aminosalicylates?
173. Editorial: clinical outcomes in lean NAFLD—the devil is in the details.
174. Editorial: first‐degree relatives of Mexican Americans with HCC are at increased risk of significant fibrosis.
175. Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation.
176. Editorial: Heal thyself—Autologous therapy for perianal Crohn's disease. Authors' reply.
177. Editorial: Heal thyself—Autologous therapy for perianal Crohn's disease.
178. Editorial: Interdisciplinary and multidisciplinary approach to malnutrition in patients with inflammatory bowel disease.
179. Editorial: deja vu all over again—let the P‐CAB wars begin.
180. Letter: should we abandon FIB‐4 to characterise noninvasively patients with NAFLD? Authors' reply.
181. Letter: dietitians are more than coaches.
182. Editorial: deja vu all over again – let the P‐CAB wars begin. Authors' reply.
183. Letter: be careful of gastrointestinal CMV infection in adverse event from ICIs therapy in solid tumours—Authors' reply.
184. Letter: Low to moderate alcohol intake and progression of non‐alcoholic fatty liver disease.
185. Letter: should we abandon FIB‐4 to characterise non‐invasively patients with NAFLD?
186. Editorial: risankizumab – ready to break ceilings?
187. Letter: trial of antitubercular therapy for diagnosing Crohn's disease in LMICs—double whammy?
188. Editorial: severe colitis induced by targeted therapies in dermato‐oncology beyond check point‐inhibitors.
189. Editorial: real‐world evidence of tofacitinib and vedolizumab in ulcerative colitis—are we one step closer to better positioning therapies after anti‐TNF failure? Authors' reply.
190. Editorial: definition of factors associated with poor quality of life in patients with IBS—but where to from here? Authorsʼ reply.
191. Letter: tofacitinib in the real world – do clinical trial data stand up?
192. Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients—authors' reply.
193. Editorial: definition of factors associated with poor quality of life in patients with IBS—but where to from here?
194. Letter: comment on Park et al – the association of non‐alcoholic fatty liver disease between parents and adolescent children.
195. Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in patients with inflammatory bowel disease.
196. Editorial: real‐world evidence of tofacitinib and vedolizumab in ulcerative colitis—are we one step closer to better positioning therapies after anti‐TNF failure?
197. Editorial: let's get physical—long‐term benefits of vigorous physical activity in patients with nonalcoholic fatty liver disease. Authors' reply.
198. Editorial: let's get physical—long‐term benefits of vigorous physical activity in patients with nonalcoholic fatty liver disease.
199. Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patients.
200. Letter: improved alanine aminotransferase level in non‐cirrhotic and low‐viral load chronic hepatitis B patients treated with nucleotide/nucleoside analogues —authorsʼ reply.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.